Evidence map›Paper›PMID 10510442›Full record

ArticleBritish journal of pharmacology1999

Anti-spasmogenic activity of isoenzyme-selective phosphodiesterase inhibitors in guinea-pig trachealis.

M M Bernareggi, M G Belvisi, H Patel, P J Barnes, M A Giembycz

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Effects of Extracts and Flavonoids fromMolecules (Basel, Switzerland) · 2022
    Article
  3. Vasorelaxant Effects of theEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  4. Review
  5. The vagal ganglia transcriptome identifies candidate therapeutics for airway hyperreactivity.American journal of physiology. Lung cellular and molecular physiology · 2018
    Article
  6. Article
  7. Using guinea pigs in studies relevant to asthma and COPD.Pulmonary pharmacology & therapeutics · 2008
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

M M BernareggiThoracic Medicine, Imperial College School of Medicine at the National Heart and Lung Institute, Dovehouse Street, London SW3 6LY.
M G Belvisi
H Patel
P J Barnes
M A Giembycz
Lung Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

1 The anti-spasmogenic potential of SK&F 94120 (PDE3-selective), rolipram (PDE4-selective), zaprinast (PDE5-selective), zardaverine (dual PDE3/4 inhibitor) and theophylline (non-selective) was evaluated in guinea-pig trachealis. 2 SK&F 94120 or rolipram (10 and 100 microM) antagonized histamine-induced tension generation in a concentration-dependent and non-competitive manner whereas ACh-induced contractions were unaffected. Similarly, SK&F 94120 and rolipram in combination were anti-spasmogenic with respect to both contractile agonists to an extent that was greater than the effect of either drug alone. Identical results were obtained with zardaverine (1, 10 and 100 microM) and theophylline (100 microM and 1 mM). 3 Zaprinast protected guinea-pig trachealis against histamine-, but not ACh-induced contractile responses in a manner that was indistinguishable from the results obtained with SK&F 94120. However, in contrast to the interaction between SK&F 94120 and rolipram, no further antagonism was seen when zaprinast and rolipram were used in combination. 4 Pre-treatment of tissues with SNP (10 and 100 microM) antagonized histamine-induced tension generation in a concentration-dependent and non-competitive manner. However, no further antagonism was produced when SNP and rolipram were used concurrently. Likewise, the protection afforded by a combination SNP and SK&F 94120 was no greater than that produced by SNP alone. 5 These results demonstrate that an inhibitor of PDE3 enhances the anti-spasmogenic activity of rolipram but not drugs that elevate cyclic GMP mass. Moreover, the ability of SNP and zaprinast to protect guinea-pig trachealis against histamine-induced contractions apparently is not due to the inhibition of PDE3.

Indexed as

3',5'-Cyclic-AMP PhosphodiesterasesAcetylcholineAnimalsAntihypertensive AgentsCardiotonic AgentsCyclic Nucleotide Phosphodiesterases, Type 3Cyclic Nucleotide Phosphodiesterases, Type 4Guinea PigsHistamineIn Vitro TechniquesIsoenzymesMaleMuscle ContractionMuscle, SmoothNitroprussideParasympatholytics3',5'-Cyclic-AMP Phosphodiesterases5-(4-acetamidophenyl)pyrazin-2(1H)-oneAcetylcholineAntihypertensive AgentsCardiotonic AgentsCyclic Nucleotide Phosphodiesterases, Type 3Cyclic Nucleotide Phosphodiesterases, Type 4HistamineIsoenzymesNitroprussideParasympatholyticsPhosphodiesterase InhibitorsPhosphoric Diester HydrolasesPyrazines

Identifiers

PMID10510442
PMCPMC1571632
OpenAlexW1984062113

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.